Indivior Plc shares fell after it lost a U.S. appeals court bid that might have forced Dr. Reddy’s Laboratories Ltd. to stop selling a generic version of the opioid addiction treatment Suboxone Film.
Dr. Reddy’s doesn’t infringe two patents on the drug owned by Aquestive Therapeutics Inc. and licensed to Indivior, the U.S. Court of Appeals for the Federal Circuit said in an opinion on its electronic docket. The three-judge appeals court panel affirmed a trial judge’s finding that Teva Pharmaceuticals Industries Ltd. infringes one of the patents, and also upheld the validity of both patents.
Indivior’s drug has been ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.